|Market Size in 2018||Market Forecast in 2026||CAGR (in %)||Base Year|
|USD 12.1 Billion||USD 22.3 Billion||9.2%||2018|
Lymphoma Treatment Market
According to the report, global demand for lymphoma treatment market was valued at approximately USD 12.1 Billion in 2018, and is expected to generate revenue of around USD 22.3 Billion by end of 2025, growing at a CAGR of around 9.2% between 2019 and 2025.
The report covers forecast and analysis for the lymphoma treatment market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the lymphoma treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the lymphoma treatment market on a global as well as regional level.
In order to give the users of this report a comprehensive view on the lymphoma treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product and services segment is benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the lymphoma treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the lymphoma treatment market on global and regional basis.
Lymphoma is a cancer that arises in infection-combatting cells of the immune system, known as lymphocytes. Such cells are in the spleen, lymph nodes, bone marrow, thymus, and other portions of the body. In lymphoma, lymphocytes modify and develop out of control. There are two key types of lymphoma: Non-Hodgkin Lymphoma and Hodgkin Lymphoma.
Factors such as increasing lymphoma cases, launch of new drugs will act as major driving factors in the growth of global lymphoma treatment market. FDA approvals and efforts taken by governments to create awareness will act as an opportunity for the market players in the lymphoma treatment market. Nonetheless, lack of awareness, high cost of lymphoma drugs, and dearth of skilled researchers will restrict the growth of global lymphoma treatment market.
The global lymphoma treatment market has been split into type, drug, and region. Based on type, lymphoma treatment market has been segmented into non-Hodgkin lymphoma and Hodgkin lymphoma. The non-Hodgkin lymphoma segment accounted for the highest market share in 2018 due to availability of treatment options. The drug segment has been segmented into opdivo, adcetris, rituxan, keytruda, revlimid, imbruvica, and others. The revlimid segment accounted for the highest market share in 2018.
North America will be the leading region during the forecast period. High investment in research and development of lymphoma treatment and presence of major manufacturers will boost the market growth in this region. Europe is expected to be the second major market. The key reasons are presence of key market players and advantageous reimbursement scenario. Asia Pacific will grow at rapid rate over the forecast time-frame due to launch of novel products. The market in Latin America will grow at a substantial rate during the estimate period. The Africa and Middle Eastern region is expected to exhibit definite progression in the anticipated time-frame.
|Report Attributes||Report Details|
|Report Name||Lymphoma Treatment Market Size Report|
|Market Size in 2018||USD 12.1 Billion|
|Market Forecast in 2026||USD 22.3 Billion|
|Growth Rate||CAGR of 9.2%|
|Number of Pages||188|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Key Companies Covered||Celgene Corporation, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Seattle Genetics, Inc., Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Abbott Laboratories, and Eli Lilly and Company among others|
|Segments Covered||By Type, By Application And By Region.|
|Historical Year||2015 to 2018|
|Forecast Year||2019 - 2025|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
The report also includes detailed profiles of key players such as Celgene Corporation, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Seattle Genetics, Inc., Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Abbott Laboratories, and Eli Lilly and Company among others.
Global Lymphoma Treatment Market: By Type
Global Lymphoma Treatment Market: By Drug
Global Lymphoma Treatment Market: By Region